Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of
There is plenty of evidence that next-generation sequencing (NGS) for lung cancer can improve patient outcomes and save healthcare systems money, but access across Europe
Precision medicine is becoming the norm in life sciences research but obstacles such as limited reimbursement for tests are hindering progress, according to a new survey.